Lineage Cell Therapeutics (LCTX) Cash from Operations (2010 - 2026)

Lineage Cell Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 8078000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 65.33% year-over-year to 8078000.0; the TTM figure through Mar 2026 stood at 22111000.0 (changed 0.38% YoY), while the FY2025 annual figure was 18919000.0, up 18.07% from the prior year.
• Cash from Operations for Q1 2026 stood at 8078000.0, down from 4878000.0 in the prior quarter.
• The five-year high for Cash from Operations was 21904000.0 in Q1 2022, with the low at 11242000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 5783000.0 (2024), against an average of 4564470.59.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations soared 395.04% in 2022, then sank 151.32% in 2023.
• Lineage Cell Therapeutics' Cash from Operations stood at 8303000.0 in 2022, then advanced by 27.51% to 6019000.0 in 2023, then decreased by 5.43% to 6346000.0 in 2024, then advanced by 23.13% to 4878000.0 in 2025, then tumbled by 65.6% to 8078000.0 in 2026.
• Business Quant data shows LCTX's Cash from Operations at 8078000.0 in Q1 2026, 4878000.0 in Q4 2025, and 3616000.0 in Q3 2025.